Collegium Pharmaceutical, Inc.

Valuation Analysis

About the Company

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Sympr

Collegium Pharmaceutical, Inc. Stock at a Glance

Collegium Pharmaceutical, Inc. (COLL) is currently trading at $34.64 with a market capitalization of $1.1B. The trailing P/E ratio stands at 16.82x, with a forward P/E of 4.55x. The 52-week range spans from $29.11 to $50.79; the current price is 31.8% below the yearly high. Year-over-year revenue growth stands at +8.9%. The net profit margin stands at 9.41%.

💰 Dividend

Collegium Pharmaceutical, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

6 analysts rate Collegium Pharmaceutical, Inc. (COLL) on consensus: None. The average price target is $54.33, implying +56.85% from the current price. Analyst price targets range from $45.00 to $60.00.

Collegium Pharmaceutical, Inc.: The Investment Case in Detail

Collegium Pharmaceutical, Inc. (COLL) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

With a gross margin near 89.17%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 27.41% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

The Bear Case

The debt-to-equity ratio of 297.57% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn. Short interest sits at 20.88% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valuation in Context

The EV/EBITDA multiple of 3.84x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

What to Watch Next

• The forward P/E of 4.55x is meaningfully below the trailing 16.82x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 56.85% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (20.88%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Collegium Pharmaceutical, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.